High Prevalence of Claudin 18.2 Expression in Japanese Patients with Gastric Cancer.

被引：3
|
作者：
Tureci, Ozlem
Itoh, Kyogo
Yamaguchi, Rin
Mukhina, Svetlana
Sahin, Ugur
Rohde, Christoph
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e15584
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15584
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer
    Kubota, Yohei
    Shitara, Kohei
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [32] Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer
    Hong, Jung Yong
    An, Ji Yeong
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kim, Kyoung-Mee
    Kang, Won Ki
    Kim, Seung Tae
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (05) : 3367 - 3374
  • [33] Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression
    Kim, Hyung-Don
    Shin, Jinho
    Hyung, Jaewon
    Lee, Hyungeun
    Moon, Meesun
    Ma, Jeongeun
    Park, Young Soo
    Ryu, Min-Hee
    GASTRIC CANCER, 2025, 28 (01) : 74 - 82
  • [34] Ectopic claudin 6 and 18.2 expression as potential treatment target in non-small cell lung cancer.
    Mattsson, Johanna S. M.
    Micke, Patrick
    Edlund, Karolina
    Lohr, Miriam
    Jirstrom, Karin
    Berglund, Anders
    Botling, Johan
    Rahnenfuehrer, Joerg
    Marincevic, Millaray
    Ponten, Fredrik
    Ekman, Simon
    Hengstler, Jan G.
    Woell, Stefan
    Sahin, Ugur
    Tuereci, Oezlem
    CLINICAL CANCER RESEARCH, 2014, 20
  • [35] Prevalence of claudin 18.2 expression in gastric/gastroesophageal junction adenocarcinoma among patients in TranStar101 and TranStar102 clinical trials
    Shen, Li
    Mao, Carol
    Lin, Alan
    Gu, Ying
    Milata, Jenny
    Zhang, Lijuan
    Qi, Chuan
    Yao, Jenny
    Yu, Steven
    Yue, Changjun
    Shen, Lin
    Janjigian, Yelena
    Qian, Xueming
    Chang, Wen-I
    Germa, Caroline
    CANCER RESEARCH, 2024, 84 (06)
  • [36] The prevalence of colorectal polyps in patients with gastric cancer.
    Kwon, Kyoung-Joo
    Shim, Ki-Nam
    Jung, Sung-Ae
    Jung, Hye-Kyung
    Kim, Seong-Eun
    Kong, Kyoung Ae
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [37] Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer
    Kim, T. Y.
    Kwak, Y.
    Nam, S. K.
    Han, D.
    Oh, D. Y.
    Im, S. A.
    Lee, H. S.
    ESMO OPEN, 2024, 9 (12)
  • [38] Progress of Clinical Studies Targeting Claudin18.2 for the Treatment of Gastric Cancer
    Jin, Wu-mei
    Zhu, Yan
    Cai, Zhi-qiang
    He, Na
    Yu, Zhi-qiong
    Li, Shuang
    Yang, Ji-yuan
    DIGESTIVE DISEASES AND SCIENCES, 2024, 69 (07) : 2631 - 2647
  • [39] FDA approves first claudin-18.2-targeted antibody for gastric cancer
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (12) : 884 - 884
  • [40] Prevalence of claudin 18.2 (CLDN18.2) and the association of biomarkers with clinical activity in patients with gastric or gastroesophageal adenocarcinoma (G/GEJa) treated with zolbetuximab.
    Moran, Diarmuid Martin
    Guerrero, Abraham
    Ueno, Yoko
    Park, Jung Wook
    Pavese, Janet
    Kaneko, Yuichiro
    Matsangou, Maria
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 466 - 466
12345